Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lymphoma
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
By
Chase Doyle
Leukemia
,
Lymphoma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Targeted therapy with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence), which is currently approved for the treatment of patients with non-Hodgkin lymphoma, has demonstrated durable remissions in treatment-naïve patients with chronic lymphocytic leukemia (CLL), according to the long-term data from the phase 2 CLL-001 study, which were presented at the ASCO 2020 virtual annual meeting.
Read Article
Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma
By
Chase Doyle
Lymphoma
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—Tazemetostat (Tazverik), a first-in-class, oral, selective EZH2 inhibitor, has demonstrated single-agent antitumor activity in patients with relapsed or refractory follicular lymphoma, according to results of a phase 2 clinical trial presented at ASH 2019.
Read Article
Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma
By
Wayne Kuznar
Lymphoma
,
Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—Nivolumab (Opdivo) monotherapy can be used as an effective bridge therapy to autologous stem-cell transplant (ASCT) in many patients with relapsed or refractory Hodgkin lymphoma, reported Matthew Mei, MD, Assistant Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, at ASH 2019.
Read Article
November 25, 2019 – Oncology News & Updates
By
Yvette Florio Lane
FDA Approvals, News & Updates
,
In the News
,
Leukemia
,
Lung Cancer
,
Lymphoma
Web Exclusives
Read Article
In This Article
Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
November 18, 2019 — Oncology News & Updates
By
Yvette Florio Lane
FDA Approvals, News & Updates
,
Hepatocellular Carcinoma
,
In the News
,
Lymphoma
Web Exclusives
Read Article
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
In the Literature
,
Lymphoma
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
The 2 chimeric antigen receptor (CAR) T-cell therapies available so far—axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)—may be considered cost-effective treatments for adults with diffuse large B-cell lymphoma (DLBCL), depending on the long-term outcomes of these patients, according to a recent cost-effective analysis (Lin JK, et al.
J Clin Oncol.
2019 Jun 3. Epub ahead of print).
Read Article
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
FDA Approvals, News & Updates
,
Lymphoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
On June 10, 2019, the FDA granted accelerated approval to polatuzumab vedotin-piiq (Polivy; Genentech), a CD79b-directed antibody–drug conjugate, in combination with bendamustine (Bendeka, Treanda) plus rituximab (Rituxan or a biosimilar), for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received ≥2 lines of therapy. The FDA granted polatuzumab breakthrough therapy and orphan drug designations.
Read Article
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
On May 28, 2019, the FDA approved lenalidomide (Revlimid; Celgene), in combination with rituximab (Rituxan), for the treatment of patients with previously treated follicular lymphoma or marginal-zone lymphoma (MZL). The FDA used its priority review program for this approval, and granted lenalidomide plus rituximab an orphan drug designation for this new indication.
Read Article
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
2019 Fourth Annual Oncology Guide to New FDA Approvals
Chronic lymphocytic leukemia (CLL) is a cancer of B-cell lymphocytes and is the most common type of leukemia in adults. More than 20,000 Americans were diagnosed with CLL in 2018.
Read Article
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Lymphoma
2019 Fourth Annual Oncology Guide to New FDA Approvals
In 1944, Jan G. Waldenström, MD, published his observations about a series of patients who presented with anemia, hepatosplenomegaly, hyperviscosity, bleeding, lymphoplasmacytic infiltrate in the bone marrow, and a large serum protein or “macroglobulin.” Today, Waldenström’s macroglobulinemia, also known as lymphoplasmacytic lymphoma, a type of non-Hodgkin lymphoma, is classified as a rare, indolent, and heterogeneous type of lymphoma of the lymphatic system.
Read Article
Page 3 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma